PRIMA-1 selectively induces global DNA demethylation in p53 mutant-type thyroid cancer cells

Journal of Biomedical Nanotechnology

Volumn 10, Issue 7, 2014, Pages 1249-1258

  Qiang, Wei ^a   Jin, Tianbo ^b,c   Yang, Qi ^a   Liu, Wei ^a   Liu, Shu ^a   Ji, Meiju ^a   He, Nongyue ^d   Chen, Chao ^b,c   Shi, Bingyin ^a   Hou, Peng ^a  

^a MEDICAL SCHOOL OF XI AN JIAOTONG UNIVERSITY   (China)

^b NORTHWEST UNIVERSITY   (China)

^c National Engineering Research Center for Miniaturized Detection System   (China)

^d SOUTHEAST UNIVERSITY   (China)

Author keywords

DNA demethylation; PRIMA 1; Thyroid cancer cells; Tumor suppressor p53

Indexed keywords

ALKYLATION; CELL CULTURE; CELL DEATH; DATA PRIVACY; DISEASES; DNA; TUMORS;

ANTICANCER ACTIVITIES; BIOLOGICAL EFFECTS; CELLULAR SENESCENCE; DNA DEMETHYLATION; DNA METHYLTRANSFERASES; PRIMA-1; THYROID CANCERS; TUMOR SUPPRESSORS;

NETWORK SECURITY;

DNA METHYLTRANSFERASE 1; DNA METHYLTRANSFERASE 3A; DNA METHYLTRANSFERASE 3B; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45; P53 REACTIVATION AND INDUCTION OF MASSIVE APOPTOSIS 1 PROTEIN; PROTEIN BAX; PROTEIN P16; PROTEIN P21; PROTEIN P53; TEN ELEVEN TRANSLOCATION 1 PROTEIN; TEN ELEVEN TRANSLOCATION 2 PROTEIN; TEN ELEVEN TRANSLOCATION 3 PROTEIN; UNCLASSIFIED DRUG; UVOMORULIN; 2,2-BIS(HYDROXYMETHYL)-1-AZABICYCLO(2,2,2,)OCTAN-3-ONE; 5-HYDROXYMETHYLCYTOSINE; CELL CYCLE PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYTOSINE; DNA (CYTOSINE 5) METHYLTRANSFERASE; DNA BINDING PROTEIN; FUSED HETEROCYCLIC RINGS; GADD45A PROTEIN, HUMAN; HETEROCYCLIC COMPOUND; NUCLEAR PROTEIN; ONCOPROTEIN; TET1 PROTEIN, HUMAN;

ARTICLE; CANCER CELL CULTURE; CELL GROWTH; CELL PROLIFERATION; DEMETHYLATION; DNA METHYLATION; DNA METHYLATION ASSAY; DOWN REGULATION; EMBOLIZATION COIL; ENZYME INHIBITION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; LUMINOMETRIC METHYLATION ASSAY; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; THYROID CANCER; UPREGULATION; ANALOGS AND DERIVATIVES; BIOLOGICAL MODEL; DRUG EFFECTS; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MUTATION; PATHOLOGY; THYROID NEOPLASMS; TUMOR CELL LINE;

AZA COMPOUNDS; BCL-2-ASSOCIATED X PROTEIN; BICYCLO COMPOUNDS, HETEROCYCLIC; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYTOSINE; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA METHYLATION; DNA-BINDING PROTEINS; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MODELS, BIOLOGICAL; MUTATION; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS; THYROID NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 84899066405     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2014.1862     Document Type: Article

References (48)

1. A. Jemal, F. Bray, M. M. Center, J. Ferlay, E. Ward, and D. Forman, Global cancer statistics. CA. Cancer J. Clin. 61, 69 (2011).
2. Y. E. Nikiforov and M. N. Nikiforova, Molecular genetics and diagnosis of thyroid cancer. Nat. Rev. Endocrinol. 7, 569 (2011).
3. M. Xing, Molecular pathogenesis and mechanisms of thyroid cancer. Nat. Rev. Cancer 13, 184 (2012).
4. R. M. Tuttle, D. W. Ball, D. Byrd, R. A. Dilawari, G. M. Doherty, Q. Y. Duh, H. Ehya, W. B. Farrar, R. I Haddad, F. Kandeel, R. T. Kloos, P. Kopp, D. M. Lamonica, T. R. Loree, W. M. Lydiatt, J. C. McCaffrey, J. A. Jr. Olson, L. Parks, J. A. Ridge, J. P. Shah, S. I. Sherman, C. Sturgeon, S. G. Waguespack, T. N. Wang, and L. J. Wirth, National comprehensive cancer network, thyroid carcinoma. J. Natl. Compr. Canc. Netw. 8, 1228 (2010).
5. K. N. Patel and A. R. Shaha, Poorly differentiated and anaplastic thyroid cancer. Cancer Control 13, 119 (2006).
6. R. O. Wein and R. S. Weber, Anaplastic thyroid carcinoma: Palliation or treatment? Curr. Opin. Otolaryngol. Head Neck Surg. 19, 113 (2011).
7. P. Hou, D. Liu, Y. Shan, S. Hu, K. Studeman, S. Condouris, Y. Wang, A. Trink, A. K. El-Naggar, G. Tallini, V. Vasko, and M. Xing, Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer. Clin. Cancer Res. 13, 1161 (2007).
8. Z. Liu, P. Hou, M. Ji, H. Guan, K. Studeman, K. Jensen, V. Vasko, A. K. El-Naggar, and M. Xing, Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers. J. Clin. Endocrinol. Metab. 93, 3106 (2008).
9. R. M. Quiros, H. G. Ding, P. Gattuso, R. A. Prinz, and X. Xu, Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations. Cancer 103, 2261 (2005).
10. H. M. Wang, Y. W. Huang, J. S. Huang, C. H. Wang, V. C. Kok, C. M. Hung, H. M. Chen, and C. Y. Tzen, Anaplastic carcinoma of the thyroid arising more often from follicular carcinoma than papillary carcinoma. Ann. Surg. Oncol. 14, 3011 (2007).
11. G. Gauchotte, C. Philippe, S. Lacomme, B. Léotard, M. P. Wissler, L. Allou, B. Toussaint, M. Klein, J. M. Vignaud, and A. Bressenot, BRAF, p53 and SOX2 in anaplastic thyroid carcinoma: Evidence for multistep carcinogenesis. Pathology 43, 447 (2011).
12. K. H. Vousden and X. Lu, Live or let die: The cell's response to p53, Nat. Rev. Cancer 2, 594 (2002).
13. D. Lane, Curing cancer with p53. N. Engl. J. Med. 350, 2711 (2004).
14. M. Hollstein, D. Sidransky, B. Vogelstein, and C. C. Harris, p53 mutations in human cancers. Science 253, 49 (1991).
15. M. Olivier, R. Eeles, M. Hollstein, M. A. Khan, C. C. Harris, and P. Hainaut, The IARC TP53 database: New online mutation analysis and recommendations to users. Hum. Mutat. 19, 607 (2002).
16. N. R. Farid, P53 mutations in thyroid carcinoma: Tidings from an old foe. J. Endocrinol. Invest. 24, 536 (2001).
17. J. M. Lambert, P. Gorzov, D. B. Veprintsev, M. Söderqvist, D. Segerbäck, J. Bergman, A. R. Fersht, P. Hainaut, K. G. Wiman, and V. J. Bykov, PRIMA-1 reactivates mutant p53 by covalent binding to the core domain. Cancer Cell 15, 376 (2009).
18. V. J. Bykov, N. Issaeva, G. Selivanova, and K. G. Wiman, Mutant p53-dependent growth suppression distinguishes PRIMA-1 from known anticancer drugs: A statistical analysis of information in the National Cancer Institute database. Carcinogenesis 23, 2011 (2002).
19. D. Russo, L. Ottaggio, I. Penna, G. Foggetti, G. Fronza, A. Inga, and P. Menichini, PRIMA-1 cytotoxicity correlates with nucleolar localization and degradation of mutant p53 in breast cancer cells. Biochem. Biophys. Res. Commun. 402, 345 (2010).
20. N. Rokaeus, G. Klein, K. G. Wiman, L. Szekely, and K. Matttsson, PRIMA-1 (MET) induces nucleolar accumulation of mutant p53 and PML nuclear body-associated proteins. Oncogene 26, 982 (2007).
21. N. Rokaeus, J. Shen, I. Eckhardt, V. J. Bykov, K. G. Wiman, M. T. Wilhelm, PRIMA-1 (MET)/APR-246 targets mutant forms of p53 family members p63 and p73. Oncogene 29, 6442 (2010).
22. R. L. Messina, M. Sanfilippo, V. Vella, G. Pandini, P. Vigneri, M. L. Nicolosi, F. Gianì, R. Vigneri, and F. Frasca, Reactivation of p53 mutants by prima-1 [corrected] in thyroid cancer cells. Int. J. Cancer 130, 2259 (2012).
23. P. A. Jones and S. B. Baylin, The fundamental role of epigenetic events in cancer. Nat. Rev. Genet. 3, 415(2002).
24. S. B. Baylin and P. A. Jones, A decade of exploring the cancer epigenome - Biological and translational implications. Nat. Rev. Cancer 11, 726 (2011).
25. S. Welkos and A. O'Brien, Determination of median lethal and infectious doses in animal model systems. Methods Enzymol. 235, 29 (1994).
26. M. Karimi, S. Johansson, and T. J. Ekström, Using LUMA: A Luminometric-based assay for global DNA-methylation. Epigenetics 1, 45 (2006).
27. M. Karimi, S. Johansson, D. Stach, M. Corcoran, D. Grandér, M. Schalling, G. Bakalkin, F. Lyko, C. Larsson, and T. J. Ekström, LUMA (LUminometric Methylation Assay) - a high throughput method to the analysis of genomic DNA methylation. Exp. Cell Res. 312, 1989 (2006).
28. Y. Liang, C. Besch-Williford, and S. M. Hyder, PRIMA-1 inhibits growth of breast cancer cells by re-activating mutant p53 protein. Int. J. Oncol. 35, 1015 (2009).
29. E. J. Peterson, O. Bögler, and S. M. Taylor, p53-mediated repression of DNA methyltransferase 1 expression by specific DNA binding. Cancer Res. 63, 6579 (2003).
30. Z. Guo, M. H. Tsai, Y. H. Shiao, L. H. Chen, M. L. Wei, X. Lv, D. Gius, J. B. Little, J. B. Mitchell, and E. Y. Chuang, DNA (cytosine-5)- methyltransferase 1 as a mediator of mutant p53-determined p16(ink4A) down-regulation. J. Biomed. Sci. 15, 163 (2008).
31. J. C. Cheng, N. Auersperg, and P. C. Leung, Inhibition of p53 represses E-cadherin expression by increasing DNA methyltransferase-1 and promoter methylation in serous borderline ovarian tumor cells. Oncogene 30, 3930 (2011).
32. D. K. Ma, J. U. Guo, G. L. Ming, and H. Song, DNA excision repair proteins and Gadd45 as molecular players for active DNA demethylation. Cell Cycle 8, 1526 (2009).
33. C. Niehrs and A. Schäfer, Active DNA demethylation by Gadd45 and DNA repair. Trends Cell Biol. 22, 220 (2012).
34. B. Lee, A. Morano, A. Porcellini, and M. T. Muller, GADD45α inhibition of DNMT1 dependent DNA methylation during homology directed DNA repair. Nucleic Acids Res. 40, 2481 (2012).
35. P. Hajkova, S. J. Jeffries, C. Lee, N. Miller, S. P. Jackson, and M. A. Surani, Genome-wide reprogramming in the mouse germ line entails the base excision repair pathway. Science 329, 78 (2010).
36. S. Ito, A. C. D'Alessio, O. V. Taranova, K. Hong, L. C. Sowers, and Y. Zhang, Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification. Nature 466, 1129 (2010).
37. S. C. Wu and Y. Zhang, Active DNA demethylation: Many roads lead to Rome. Nat. Rev. Mol. Cell Biol. 11, 607 (2010).
38. A. Sigal and V. Rotter, Oncogenic mutations of the p53 tumor suppressor: The demons of the guardian of the genome. Cancer Res. 60, 6788(2000).
39. C. P. Martins, L. Brown-Swigart, and G. I. Evan, Modeling the therapeutic efficacy of p53 restoration in tumors. Cell 127, 1323 (2006).
40. A. Ventura, D. G. Kirsch, M. E. McLaughlin, D. A. Tuveson, J. Grimm, L. Lintault, J. Newman, E. E. Reczek, R. Weissleder, and T. Jacks, Restorationof p53 function leads to tumour regression in vivo. Nature 445, 661 (2007).
41. K. G. Wiman, Pharmacological reactivation of mutant p53: From protein structure to the cancer patient. Oncogene 29, 4245 (2010).
42. X. Cheng and R. M. Blumenthal, Mammalian DNA methyltransferases: A structural perspective. Structure 16, 341 (2008).
43. I. Qayum and M. Ashraf, Dna methyltransferase 1 (DNMT1) gene activity in human lymphomas correlates with aberrant p53 gene expression. J. Ayub. Med. Coll. Abbottabad. 18, 1 (2006).
44. R. K. Lin, C. Y. Wu, J. W. Chang, L. J. Juan, H. S. Hsu, C. Y. Chen, Y. Y. Lu, Y. A. Tang, Y. C. Yang, P. C. Yang, and Y. C. Wang, Dysregulation of p53/Sp1 control leads to DNA methyltransferase-1 overexpression in lung cancer. Cancer Res. 70, 5807 (2010).
45. G. Barreto, A. Schäfer, J. Marhold, D. Stach, S. K. Swaminathan, V. Handa, G. Döderlein, N. Maltry, W. Wu, F. Lyko, and C. Niehrs, Gadd45a promotes epigenetic gene activation by repair-mediated DNA demethylation. Nature 445, 671 (2007).
46. M. Tahiliani, K. P. Koh, Y. Shen, W. A. Pastor, H. Bandukwala, Y. Brudno, S. Agarwal, L. M. Iyer, D. R. Liu, L. Aravind, and A. Rao, Conversion of 5-methycytosine to 5-hydromethycytosine in mammalian DNA by MLL partner TET1. Science 324, 930 (2009).
47. Q. Yang, K. Wu, M. Ji, W. Jin, N. He, B. Shi, and P. Hou, Decreased 5-hydroxymethylcytosine (5-hmC) is an independent poor prognostic factor in gastric cancer patients. J. Biomed. Nanotechnol. 9, 1607 (2013).
48. Y. Li, Y. Zhu, K. Szulwach, L. Lin, C. Street, H. Wu, D. Chen, and P. Jin, P53 regulates 5-hydroxymethylcytosine-mediated epigenetic landscape through GADD45A, Proceedings of the 2012 Annual Meeting of American Society Human Genetics, San Francisco, USA, November (2012).